| 
 | |||||
|   | 
| 
 | 

Transmission provider Allison Transmission (NYSE:ALSN) fell short of the markets revenue expectations in Q3 CY2025, with sales falling 15.9% year on year to $693 million. The company’s full-year revenue guidance of $3 billion at the midpoint came in 2.2% below analysts’ estimates. Its GAAP profit of $1.63 per share was 11.5% below analysts’ consensus estimates.
Is now the time to buy ALSN? Find out in our full research report (it’s free for active Edge members).
Allison Transmission’s third quarter was marked by a significant year-over-year revenue decline and a negative market reaction, reflecting broader macroeconomic pressures and ongoing uncertainty in its largest end market, North America On-Highway. Management attributed the underperformance primarily to subdued commercial vehicle demand driven by external factors such as tariffs, changing trade policies, and upcoming emissions regulations. CEO David Graziosi described the environment as one of “extraordinary and volatile global macroeconomic factors,” noting that these challenges led end users to defer purchases and made demand visibility more difficult.
Looking forward, Allison’s revised outlook is shaped by continued uncertainty in North American truck demand and an evolving global regulatory landscape. Management emphasized its focus on operational flexibility and highlighted ongoing efforts to close the Dana Off-Highway acquisition as a strategic move. CFO Scott Mell stated the company is maintaining a disciplined approach to cost management and capital allocation, while COO Fred Bohley pointed to pricing initiatives and international expansion as areas of potential growth. Management remains cautious, indicating that a meaningful improvement will depend on greater clarity around economic and regulatory catalysts.
Management cited a sharp downturn in North American On-Highway truck demand, offset by resilience in defense and growth initiatives outside North America, as the main drivers of the quarter’s results.
Allison’s forward-looking strategy hinges on managing through continued demand uncertainty, leveraging pricing actions, and expanding internationally, while monitoring the impact of tariffs and regulatory changes.
Looking ahead, the StockStory team will monitor (1) signs of stabilization or recovery in North America On-Highway truck demand, (2) continued execution and revenue contribution from international and defense growth initiatives, and (3) progress toward closing and integrating the Dana Off-Highway acquisition. We will also track Allison’s ability to deliver on pricing actions and cost discipline as key indicators of performance in a challenging environment.
Allison Transmission currently trades at $76.25, down from $81.55 just before the earnings. Is there an opportunity in the stock?Find out in our full research report (it’s free for active Edge members).
Donald Trump’s April 2025 "Liberation Day" tariffs sent markets into a tailspin, but stocks have since rebounded strongly, proving that knee-jerk reactions often create the best buying opportunities.
The smart money is already positioning for the next leg up. Don’t miss out on the recovery - check out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
| 5 hours | |
| 10 hours | |
| 12 hours | |
| Oct-29 | |
| Oct-29 | |
| Oct-29 | |
| Oct-29 | |
| Oct-29 | |
| Oct-29 | |
| Oct-28 | |
| Oct-28 | |
| Oct-28 | |
| Oct-27 | |
| Oct-23 | |
| Oct-23 | 
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite